SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr Reddys gets US FDA nod for Azacitidine Injection

17 Sep 2013 Evaluate

Pharma major Dr Reddys Laboratories has received US Food and Drug Administration (FDA) approval for Azacitidine Injection 100 mg/vial, a bioequivalent generic version of VIDAZA (azacitidine for injection) on September 16, 2013. The launch of product in the market is planned in the near-term.

The VIDAZA brand had U.S. sales of approximately $378.5 Million for the most recent twelve months ending July 2013 according to IMS Health.

Dr Reddy's Azacitidine for Injection 100 mg/vial is available in single use-vials.

Dr. Reddys Lab Share Price

1279.70 -13.55 (-1.05%)
11-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1279.70
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2245.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×